Angel Adegbesan is a business reporter whose work has been featured in top publications such as Fortune, Bloomberg News, Toronto Star, and The Washington Post. With a focus on the financial sector and medical industry, Angel covers topics ranging from biotech stocks and market trends to the impact of pharmaceutical drugs on various industries.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Angel Adegbesan's articles predominantly focus on investment analysis within the healthcare and pharmaceutical industry, often supported by cited data. To effectively reach out to her, consider providing well-researched insights related to stock market movements, drug development or financial impacts within the biotech and pharmaceutical sectors.
Given Angel’s emphasis on citing data in investment analysis, she may be particularly responsive to pitches that offer proprietary data or unique analyses relevant to the performance of companies in the healthcare and pharmaceutical industries.
As there is no specific geographic focus mentioned for Angel's coverage, it appears that she covers global developments in healthcare and pharmaceuticals without a particular regional bias.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Novavax Inc.'s record one-day gain is forcing some short sellers betting against the stock to exit their positions at a loss.
Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments.
By: Angel Adegbesan, Sophia Vahanvaty
Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus.
By: Sophia Vahanvaty, Angel Adegbesan
(Bloomberg) -- Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus. Most Read from BloombergManchester Is Giving London a Run for Its MoneyBoston’s Broke and Broken Transit System Hurts Downtown RecoveryA Floating Island in Baltimore Raises Hope for a Waterfront RevivalA Warehouse Store Promises Housing for
By: Angel Adegbesan
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.
“Spring forward, fall back” is a twice-a-year part of life in roughly 70 countries around the world. In the US, where the practice is more than a century old, lawmakers are considering measures that would end clock changes and make daylight saving time permanent. That would mean later sunrises and sunsets for half the year. There’s evidence that the public health effect would be mixed: fewer car accidents and heart attacks caused by time shifts, but potentially a loss of sleep quality for almost
By: Angel Adegbesan
Most Read from Bloomberg Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential
Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment.
A recently debuted nursing home operator, PACS Group Inc., made a violent reversal this week, erasing around $2.5 billion from its cofounders’ fortunes.
By: John Tozzi, Angel Adegbesan, Antonia Mufarech, David Voreacos
This is a special edition of Prognosis from Bloomberg reporters who were at the Manhattan hotel where UnitedHealth’s Brian Thompson was shot Wednesday and others who spoke with eyewitnesses.
(833) 317-6278 
